The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Seven-year efficacy and safety in a randomized phase III trial investigating duration of adjuvant oxaliplatin-based therapy (3 vs. 6 months) for patients with high-risk stage II colon cancer: ACHIEVE-2 trial.
 
Eiji Sunami
No Relationships to Disclose
 
Kentaro Yamazaki
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Manabu Shiozawa
Speakers' Bureau - Johnson & Johnson; Kaken Pharmaceutical; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Dai Manaka
No Relationships to Disclose
 
Masahito Kotaka
Honoraria - Chugai Pharma; Lilly; Takeda
 
Yasuhiro Sakamoto
Honoraria - Bristol-Myers Squibb Co. Ltd.; Chugai Pharma; Daiichi-Sankyo Co. Ltd.; Lilly Japan; MSD K.K.; Nippon Kayaku K.K. Kyowa Kirin K.K.; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Akio Shiomi
No Relationships to Disclose
 
Yudai Shinohara
No Relationships to Disclose
 
Yoshinori Munemoto
No Relationships to Disclose
 
Toshiki Rikiyama
No Relationships to Disclose
 
Mutsumi Fukunaga
No Relationships to Disclose
 
Takashi Ueki
No Relationships to Disclose
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - ALX Oncology; Amgen; Arcus Biosciences Inc.; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline K.K.; Guardant Health; Healios; Janssen; Moderna.Inc; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PPD-SNBL (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst)
 
Jun Yamada
No Relationships to Disclose
 
Nobuyuki Tanida
No Relationships to Disclose
 
Toshihiro Misumi
Honoraria - Chugai Pharma Europe; Miyarisan pharmaceutical
Consulting or Advisory Role - Anaut Inc.
 
Atsushi Ohtsu
Employment - AstraZeneca (I); Celgene (I)
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb
 
Yoshihiko Maehara
No Relationships to Disclose
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; MSD K.K.; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Molecular Health (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)